肺癌合剂配合化疗治疗中晚期非小细胞肺癌

目的:观察肺癌合剂配合化疗对中晚期非小细胞肺癌患者的临床疗效。方法:60例确诊为中晚期非小细胞肺癌患者随机分为对照组(NP或GP方案化疗)30例、治疗组(化疗+中药)30例,治疗组化疗方案同对照组,同时口服中药肺癌合剂每日2次,每次150 mL。连用2周期后,观察两组患者的近期疗效、主要症状改善情况、生活质量、体重变化、不良反应、肿瘤标志物变化等。结果:肺癌合剂配合化疗能有效改善患者的症状、提高生活质量、明显减轻化疗对骨髓、消化道等的影响、降低肿瘤标志物CEA,CA153的水平,但在瘤体大小的客观有效率和稳定率的指标上和单纯化疗相比并不具有优势。治疗组干咳、气短、神疲乏力、口干咽燥等4个症状显著改善,与对照组相比有显著性差异(P<0.05);生活质量有效率分别为76.67%,46.67%。对照组治疗前、后CEA,CA153值比较有显著性差异(P<0.05),治疗组治疗前、后CEA,CA153值比较有非常显著性差异(P<0.01)。结论:肺癌合剂配合化疗可作为中晚期非小细胞肺癌的一种有效、低毒的治疗方案。

Treatment of Advanced Non-small Cell Lung Cancer with Feiai Heji Combined with Chemotherapy

Objective: to observe the effect of Feiai Heji(FAHJ) in treating patients with advanced non-small-cell lung cancer(NSCLC). Method: Sixty patients with confirmed diagnosis of advanced NSCLC were selected and randomly divided into two groups:Thirty patients in the control group with chemotherapy alone(NP or GP regimen),Thirty patients in the treated group were administered with FAHJ and chemotherapy(the regimen was as same as the control group).After 2 cycles,two groups were observed with short-term effect,the main symptom improvement,quality of life,weight changes,adverse reactions,changes in tumor markers and other projects. Result: The improvement of clinical symptoms in the treated group were superior to those in the control group.As well as improved the QOL,decreased marrow suppression,nausea,vomit and other adverse reactions and levels of tumor marks(CEA,CA153).But there was no significant difference in the effective rates and the disease control rates between two groups. Conclusion: FAHJ combined with chemotherapy can be used as an effective,low toxicity approach to treat the advanced non-small cell lung cancer.